The Sinopharm COVID-19 (BBIBP-CorV, COVILO) is an inactivated vaccine made of virus particles grown in culture and lacks the disease-producing capability. This vaccine was developed by China National Pharmaceutical Group Co., Ltd. (Sinopharm) and the Beijing Institute of Biological Products Co in 2020.To get more news about sinopharm vaccine latest update, you can visit shine news official website.
The Sinopharm BBIBP-CorV vaccine teaches the immune system to make antibodies against the SARS-CoV-2 beta coronavirus. For several decades, inactivated virus vaccines have been successfully applied, such as vaccines against hepatitis A. In addition, this development technology has been successfully used in many well-known vaccines, such as the rabies vaccine.
Sinopharm's SARS-CoV-2 strain (WIV04 strain and GenBank number (MN996528) was isolated from a patient in the Jinyintan Hospital, Wuhan, China. The virus was cultivated in a qualified Vero cell line for propagation, and the supernatant of the infected cells was inactivated with β-propiolactone (1:4000 vol/vol at 2 to 8 °C) for 48 hours. Following clarification of cell debris and ultrafiltration, the second β-propiolactone inactivation was performed in the same conditions as the first inactivation.
On December 31, 2020, China's National Medical Products Administration announced the experimental BBIBP-CorV vaccine, developed by a State-owned Sinopharm, was Approved.
On May 7, 2021, the WHO announced the vaccine's approval, becoming Emergency Use Listed to expedite regulatory approvals to import and administer vaccines. WHO's Strategic Advisory Group of Experts on Immunization (SAGE) also completed its vaccine review. And the WHO published 'Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine.' Based on available evidence, the vaccine efficacy for symptomatic and hospitalized diseases was estimated to be 79% for all age groups combined.
On September 2, 2021, the WHO confirmed Interim recommendations for using the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm. The predecessor was the Central Epidemic Prevention Department of the Beiyang Government. In addition, the WHO Strategic Advisory Group of Experts issued recommendations for the Sinopharm COVID-19 vaccine. On October 28, 2021, the WHO announced interim guidance for using the COVID-19 vaccine BIBP produced by Sinopharm based on advice issued by the Strategic Advisory Group of Experts on Immunization and the evidence summary included in the background document and annexes reviewed.
The JAMA Network published an Original Investigation on October 29, 2021, that concluded, 'In this cohort study of 663,602 participants, the use of non-mRNA COVID-19 vaccines was associated with a significant reduction in all-cause death, COVID-related death, and documented infection with the use of 1 dose and even more with the use of 2 doses.'
The phase 3 study (HUN-VE) conducted across three continents published an interim analysis on November 25, 2021; the effectiveness of Sinopharm in preventing Covid-19 related death varied between 67.5% and 100% according to age ≥ seven days after the second dose, with an adjusted overall efficacy of 87.8%.
The Sinopharm BBIBP-CorV COVID-19 vaccine Drug Bank accession number: DB15807. CAS Number: 2503126-65-4. ATC code: J07BX03. Sinopharm BBIBP-CorV Recent Phase 3 studies: ChiCTR2000034780; NCT04510207; NCT04612972; NCT04612972. WHO Evidence Assessment in 2021.mmission
China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services. The vaccine is also manufactured by G42 Healthcare (Hayat-Vax).
| By | buzai232 |
| Added | May 31 '22, 07:13PM |
The Wall